Gain Therapeutics, Inc.
NASDAQ:GANX · NASDAQ Global Market
+$0.06 today
Vol 0.50M · Avg 0.64M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:GANX · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$21.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.58, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 -100.0% | $55.2K -60.6% | $140.1K -15.1% | $165.0K | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 -100.0% | $55.2K -60.6% | $140.1K -15.1% | $165.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $10.2M -5.4% | $10.8M -6.3% | $11.5M +37.5% | $8.4M +16.9% | $7.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $8.5M -11.1% | $9.6M -11.4% | $10.8M +13.1% | $9.5M +39.7% | $6.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $18.7M -8.1% | $20.4M -8.8% | $22.3M +24.5% | $17.9M +28.1% | $14.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $94.0K +11.9% | $84.1K +0.6% | $83.6K +30.3% | $64.2K +314.4% | $15.5K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$19.2M +3.0% | -$19.8M +10.5% | -$22.1M -26.8% | -$17.4M -25.7% | -$13.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | -40059.2% -27616.2pp | -12443.0% -4035.9pp | -8407.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$18.7M +8.1% | -$20.4M +8.5% | -$22.3M -25.2% | -$17.8M -28.6% | -$13.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | -40328.3% -27640.2pp | -12688.1% -4308.3pp | -8379.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $244.4K -31.6% | $357.1K -27.7% | $494.2K +31.7% | $375.4K +2904.1% | $12.5K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$589.3K -223.7% | $476.2K +633.9% | $64.9K -76.8% | $279.3K +562.2% | -$60.4K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$19.3M +2.9% | -$19.9M +10.4% | -$22.2M -26.8% | -$17.5M -26.0% | -$13.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | -40210.7% -27721.9pp | -12488.8% -4072.3pp | -8416.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $861.1K +60.4% | $536.8K +577.2% | $79.3K -14.7% | $93.0K +2219.8% | $4.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$20.2M +1.2% | -$20.4M +8.3% | -$22.3M -26.6% | -$17.6M -26.6% | -$13.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | -40354.3% -27799.2pp | -12555.1% -4136.3pp | -8418.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +31.5% | -$1 +48.0% | -$2 -15.5% | -$1 -8.0% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +31.5% | -$1 +48.0% | -$2 -15.5% | -$1 -8.0% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $33.0M +44.1% | $22.9M +75.9% | $13.0M +9.5% | $11.9M +16.9% | $10.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $33.0M +44.1% | $22.9M +75.9% | $13.0M +9.5% | $11.9M +16.9% | $10.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Adagene Inc.
NASDAQ:ADAG
$138.36M
Fortress Biotech, Inc.
NASDAQ:FBIO
$100.82M
OS Therapies Incorporated
AMEX:OSTX
$81.06M
Adicet Bio, Inc.
NASDAQ:ACET
$75.91M
XBiotech Inc.
NASDAQ:XBIT
$71.65M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$69.75M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.81M
Nutriband Inc.
NTRB
$38.41M
CervoMed Inc.
CRVO
$37.87M
Lite Strategy, Inc.
LITS
$29.34M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GANX generate?
Gain Therapeutics, Inc. (GANX) reported $0.00 of revenue in fiscal 2025.
Is GANX profitable?
Gain Therapeutics, Inc. (GANX) reported -$20,161,099.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.